Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
about
Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic reviewMolecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationNew concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.Survival and low-grade glioma: the emergence of genetic informationManagement of low-grade glioma.Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium studyClinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survivalSeizure prognosis in brain tumors: new insights and evidence-based managementCentral nervous system cancersMitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.Molecular classification of low-grade diffuse gliomas.Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomasProlonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomasTERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersCurrent treatment of low grade gliomasPhase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424Adult low-grade glioma: 19-year experience at a single institution.IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study.Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomideEarly treatment of complex located pediatric low-grade gliomas using iodine-125 brachytherapy alone or in combination with microsurgery.Low-grade gliomas: management issues.Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.Brain tumors and epilepsy.Comparison of long-term survival between temozolomide-based chemoradiotherapy and radiotherapy alone for patients with low-grade gliomas after surgical resection.Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective studyIntracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic.Pharmacotherapy for adults with tumors of the central nervous system.Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic.Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalitiesSeizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.
P2860
Q27027730-9A8717EA-69F3-4CA6-AD93-F6AA891C2D24Q28383205-F8CB7C3B-085B-44C2-A4A9-65FD7E3B5273Q30365386-AAA2C248-48D9-4B97-98BF-B190814871F5Q30395017-5F16184F-B170-46E8-B6D6-F1D82B28807BQ30436353-72109A95-F675-4991-8BF7-C52B0C5795A6Q30458648-44F9D529-01C6-4086-8078-0DD61957BACEQ33399939-AFFF0C9A-DC0C-4BAD-A623-D05A35B4E4B4Q33406813-8B73B839-0789-48F2-8B79-CC797146A4D1Q33815954-F40986D3-5E2E-49F1-90E9-6717904AED15Q33829789-F1201A3C-A045-4E5F-A086-E3F10FF9730DQ34014740-E5C91832-E2ED-411B-B102-98B93CF7AA64Q34062043-893F4ED3-122F-43AF-811C-50CA7EE09412Q34132650-3CDA11EF-6983-47B9-B841-0CBC0142442FQ34200021-8786140F-DB5F-45A3-8724-2A8CD3362575Q34358250-F2BFE0C8-C602-4A6D-B61D-C071B6145AC0Q34426355-C29EA874-AE3D-4C9F-8B14-527403BBA7D6Q34480589-E395B091-72EB-46E4-8594-FF8C5164A027Q34499685-EF1599F4-E2C5-432C-B6D7-98E711EC1710Q34815207-D57A011E-EFD3-4965-A043-FF73AAF78BF0Q34830708-26D16C30-425C-4B8F-88D4-B13B94F60A68Q35085561-48F3AC34-F7F8-4DBD-85CB-D2623E658921Q35183129-F7DE1377-4AC6-4C54-A309-60899D96B882Q35204658-87B9158C-B4DB-41AB-8353-C6A746D979F8Q35225228-3D1A7D68-E7BC-4AA4-9C2E-8984BFB9555AQ36037100-E5B6923E-9A34-45A8-9450-0C8A4501BF66Q36140650-F8661B44-77AB-4126-88E4-18C3404291E6Q36480099-22AEE880-C8C3-498C-8531-D6E04E1ECF3CQ36706889-3FA24FFD-7C5C-4244-9980-E858A5D53C98Q37030794-C1BF1E2B-2599-4A1A-AA21-4C2270833CC4Q37037132-C17D226A-6D0E-4185-938F-A2E6C42BE351Q37109261-E8A80182-C3C8-4B38-9DA2-4AC5878A7E7FQ37174060-323FDDF4-6C62-440C-8F6E-376E987F2E90Q37194312-D1BE8460-7856-47D4-AF8D-85700D424EA8Q37312684-E95506CF-17D7-4ED3-8BC5-52F1B2A00951Q37344962-398132D0-27F1-42C5-B794-FFA272336F7BQ37353276-45B7A6BD-1CF3-4420-A04A-99370C0DB299Q37462007-86882305-186C-48DB-82D5-2D86B3E9312CQ37900207-E4E1B5AE-0099-4FA8-B763-11417D371AFEQ38055317-B773429C-0B54-48BF-9765-B470D1E3AC12Q38055318-F30F5CA6-D9D1-4C24-B36A-2F4FCB692BC9
P2860
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Temozolomide for low-grade gli ...... loss on response and outcome.
@ast
Temozolomide for low-grade gli ...... loss on response and outcome.
@en
type
label
Temozolomide for low-grade gli ...... loss on response and outcome.
@ast
Temozolomide for low-grade gli ...... loss on response and outcome.
@en
prefLabel
Temozolomide for low-grade gli ...... loss on response and outcome.
@ast
Temozolomide for low-grade gli ...... loss on response and outcome.
@en
P2093
P1433
P1476
Temozolomide for low-grade gli ...... loss on response and outcome.
@en
P2093
A Benouaich-Amiel
A Carpentier
F Laigle-Donadey
J-Y Delattre
K Hoang-Xuan
P304
P356
10.1212/01.WNL.0000262034.26310.A2
P407
P577
2007-05-01T00:00:00Z